Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19

Suzanne E. Schindler, Gregory A. Jicha, Peter T. Nelson, C. Dirk Keene, Kaj Blennow, Jose Luis Molinuevo, Colin L. Masters, Oskar Hansson, Charlotte E. Teunissen, Douglas Galasko, Leslie M. Shaw, Allan I. Levey, Nina Silverberg

Research output: Contribution to journalArticlepeer-review

Abstract

The coronavirus disease 2019 (COVID-19) pandemic led to an abrupt halt of many Alzheimer's disease (AD) research studies at sites spanning the world. This is especially true for studies requiring in-person contact, such as studies collecting biofluids. Since COVID-19 is likely to remain a threat for an extended period, the resumption of fluid biomarker studies requires the development and implementation of procedures that minimize the risk of in-person visits to participants, staff, and individuals handling the biofluid samples. Some issues to consider include structuring the visit workflow to minimize contacts and promote social distancing; screening and/or testing participants and staff for COVID-19; wearing masks and performing hand hygiene; and precautions for handling, storing, and analyzing biofluids. AD fluid biomarker research remains a vitally important public health priority and resuming studies requires appropriate safety procedures to protect research participants and staff.

Original languageEnglish
Pages (from-to)27-31
Number of pages5
JournalJournal of Alzheimer's Disease
Volume76
Issue number1
DOIs
StatePublished - 2020

Keywords

  • Alzheimer's disease
  • COVID-19
  • biofluids
  • biomarkers
  • safety

Fingerprint Dive into the research topics of 'Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19'. Together they form a unique fingerprint.

Cite this